BIB vs. ARKG

In the year-to-date period, BIB achieves a -14.99% return, which is significantly lower than ARKG's -7.41% return. Over the past 10 years, BIB has underperformed ARKG with an annualized return of -6.59%, while ARKG has yielded a comparatively higher 0.19% annualized return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

BIB has a 0.95% expense ratio, which is higher than ARKG's 0.75% expense ratio.

This table presents a comparison of risk-adjusted performance metrics for ProShares Ultra Nasdaq Biotechnology (BIB) and ARK Genomic Revolution Multi-Sector ETF (ARKG). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current BIB Sharpe Ratio is -0.54, which is lower than the ARKG Sharpe Ratio of -0.38. The chart below compares the historical Sharpe Ratios of BIB and ARKG, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

BIB's dividend yield for the trailing twelve months is around 2.20%, while ARKG has not paid dividends to shareholders.

The maximum BIB drawdown since its inception was -67.24%, smaller than the maximum ARKG drawdown of -83.59%. Use the drawdown chart below to compare losses from any high point for BIB and ARKG. For additional features, visit the drawdowns tool.

ProShares Ultra Nasdaq Biotechnology (BIB) has a higher volatility of 20.70% compared to ARK Genomic Revolution Multi-Sector ETF (ARKG) at 14.24%. This indicates that BIB's price experiences larger fluctuations and is considered to be riskier than ARKG based on this measure. The chart below showcases a comparison of their rolling one-month volatility.